Jump to content
The World News Media

Relypsa Scores Big Win When Pharma Rival Flops at FDA - TheStreet.com

Money & Finance

Recommended Posts

  • Member

Relypsa Scores Big Win When Pharma Rival Flops at FDA
FDA rejects AstraZeneca's potassium-lowering drug, which means Relypsa's competing drug, already approved, has the commercial market all to itself. Adam Feuerstein. Follow. May 27, 2016 5:54 AM EDT. Relypsa (RLYP) scored a big win Friday after its ...
AstraZeneca's $2.7B hyperkalemia drug ZS-9 rejected by FDAFierceBiotech
AstraZeneca's CRL on ZS-9 Reduces Near Term Commercial Risk for Veltassa and Relypsa (RLYP) - WedbushStreetInsider.com
UPDATE 1-AstraZeneca potassium drug delayed by manufacturing snagReuters
MarketWatch -Benzinga -Seeking Alpha -The Guardian
all 20 news articles »


Link to comment
Share on other sites

  • Views 430
  • Replies 0
  • Created
  • Last Reply

Top Posters In This Topic

Popular Days

Top Posters In This Topic

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


  • Create New...

Important Information

Terms of Service Confirmation Terms of Use Privacy Policy Guidelines We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.